Siba Raychaudhuri, MD
Rheumatology · Palo Alto, CANPI 1821033275
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,813 of the $75,095 with a category attached, or 66.3%. It is spread thinly across 16 manufacturers, the largest accounting for just 23.7%. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $904.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Eli Lilly$11K
- UCB, Inc.$10K
- Janssen Scientific Affairs, LLC$9K
- Novartis$7K
- Johnson & Johnson$6K
- plus $13K from 10 others
Across 57 payments — averaging $10,574 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$286K
- Novartis$169K
- Eli Lilly$57K
- Pfizer$41K
- Sun Pharmaceutical Industries Inc.$28K
- Janssen Research & Development, LLC$21K
- plus $28 from 1 others
What the payments were for
- Consulting fees$49,81366%
- Speaking & faculty fees$15,50021%
- Travel & lodging$7,50110%
- Food & beverage$2,0363%
- Education$2450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $17,805 |
| Eli Lilly | 3 | $11,050 |
| UCB, Inc. | 14 | $10,107 |
| Janssen Scientific Affairs, LLC | 2 | $9,075 |
| Novartis | 6 | $7,473 |
| Johnson & Johnson | 6 | $6,168 |
| Sun Pharmaceutical Industries Inc. | 9 | $5,285 |
| UCB SA | 1 | $3,840 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $1,963 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,900 |
| Sanofi-aventis U.S. LLC | 2 | $193 |
| Genentech USA, Inc. | 1 | $91 |
| Amgen | 1 | $63 |
| Sanofi | 1 | $47 |
| Merck | 1 | $26 |
| Lilly USA, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,095 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Palo Alto
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.